Could you please provide me with following numbers of patients treated in the last 12 months (latest) 12 months possible) with the following drugs for either Rheumatology, Dermatology and Gastroenterology departments:
Abatacept (Orencia)
Adalimumab biosimilar (Amgevita)
Adalimumab biosimilar (Hulio)
Adalimumab (Humira)
Adalimumab biosimilar (Hyrimoz)
Adalimumab biosimilar (Imraldi)
Apremilast (Otezla)
Baricitinib (Olumiant)
Brodalumab (Kyntheum)
Certolizumab (Cimzia)
Dimethyl Fumarate (Skilarence)
Etanercept (Enbrel)
Etanercept Biosimilar (Benepali)
Etanercept Biosimilar (Erelzi)
Golimuab (Simponi)
Guselkumab (Tremfya)
Infliximab (Flixabi)
Infliximab (Inflectra)
Infliximab (Remicade)
Infliximab (Remsima)
Ixekizumab (Taltz)
Rituximab (Mabthera)
Rituximab Biosimilar (Rixathon)
Rituximab Biosimilar (Truxima)
Sarilumab (Kevzara)
Secukinumab (Cosentyx)
Tildrakizumab (Ilumetri)
Tocilizumab (Ro Actemra)
Tofacitinib (Xeljanz)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)

Download response Biologics and Biosimilar prescribing. 031219